FLGT
Fulgent Genetics, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 250 | $5,324 | n/a | n/a |
| Q2 2026 | 61 | -5 | 10.73M | $220.18M | +4 | −10 |
| Q1 2026 | 69 | 0 | 11.71M | $186.24M | +4 | −4 |
| Q4 2025 | 69 | +1 | 14.16M | $372.03M | +1 | n/a |
| Q3 2025 | 14 | 0 | 9.19M | $207.61M | n/a | n/a |
| Q2 2025 | 11 | -2 | 7.55M | $150.07M | n/a | −2 |
| Q1 2025 | 10 | +1 | 3.99M | $67.47M | +1 | n/a |
| Q4 2024 | 9 | -1 | 3.49M | $64.46M | n/a | −1 |
| Q3 2024 | 9 | +1 | 2.57M | $55.79M | +2 | −1 |
| Q2 2024 | 8 | n/a | 1.93M | $37.93M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | TD Waterhouse Canada Inc. | 250 | +19.1% | $5,324 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 156 holders, 16.99M shares, $249.23M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.67K sh · $32,885
Officer · 2.13K sh · $41,809
Officer · 939 sh · $18,691
Officer · 1.19K sh · $23,747
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
32.3% of class · View original SEC filing ↗